Matheus da Silva Oliveira

Matheus da Silva Oliveira

Auto-generated profile, based on publicly available information

Matheus da Silva Oliveira

Laboratório de Biologia do Câncer, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
.S.Priscyanne Barreto Siqueira
.Priscyanne Barreto Siqueira
MRMariana Moreno de Sousa Rodrigues
Mariana Moreno de Sousa Rodrigues
IAIsis Amorim
Isis Amorim
TSThayssa Gomes da Silva
Thayssa Gomes da Silva
MOMatheus da Silva Oliveira
Matheus da Silva Oliveira
AMAndre Luiz Mencalha
Andre Luiz Mencalha

1 January 2024 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
.S.Priscyanne Barreto Siqueira
.Priscyanne Barreto Siqueira
MRM.M.S. Rodrigues
M.M.S. Rodrigues
IAIsis Amorim
Isis Amorim
JRJ.A. Rodrigues
J.A. Rodrigues
MOM.S. Oliveira
M.S. Oliveira
AMA.L. Mencalha
A.L. Mencalha
Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/REF-1) is a multifunctional protein acting on cellular signaling pathways, including DNA repair and redox activities. APE1/REF-1 has emerged as a target for cancer therapy, and its role in breast cancer models would reveal new strategies for cancer therapy. APX2009 is a specific APE1/REF-1 redox inhibitor whose anticancer properties have not been described in breast cancer cells. Here, we investigated the effect of the APX2009 treatment in the breast cancer cell lines MDA-MB-231 and MCF-7. Breast cancer cell lines were cultured, and WST1 and colony formation assays were performed to evaluate cell proliferation. Annexin V-FITC/7-AAD and LDH-Glo™ assays were performed to evaluate cell death. The wound healing assay and Matrigel transwell assay were performed after APX2009 treatment to evaluate the cellular migration and invasion processes, respectively. Our findings demonstrated that APX2009 treatment decreased breast cancer cell proliferative, migratory, and invasive properties. Furthermore, it induced apoptosis in both cell lines. Our study is the first to show the effects of APX2009 treatment on apoptosis in a breast cancer cell. Therefore, this study suggested that APX2009 treatment is a promising anticancer molecule for breast cancer.

13 October 2024 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
IAIsis Amorim
Isis Amorim
DPDaphne Pinheiro
Daphne Pinheiro
MOMatheus da Silva Oliveira
Matheus da Silva Oliveira
MRMariana Moreno de Sousa Rodrigues
Mariana Moreno de Sousa Rodrigues
JJJulia Silva José
Julia Silva José
AMAndre Luiz Mencalha
Andre Luiz Mencalha